Hysbysiad dyfarnu contract
Canlyniadau'r weithdrefn gaffael
Adran I:
Endid
contractio
I.1) Enw a chyfeiriad
NHS England
7&8 Wellington Place
Leeds
LS1 4AP
UK
Person cyswllt: Anna Salt
E-bost: anna.salt@nhs.net
NUTS: UKE
Cyfeiriad(au) rhyngrwyd
Prif gyfeiriad: https://www.england.nhs.uk//
Cyfeiriad proffil y prynwr: https://www.england.nhs.uk//
I.4) Y math o awdurdod contractio
Corff a lywodraethir gan gyfraith gyhoeddus
I.5) Prif weithgaredd
Iechyd
Adran II: Gwrthrych
II.1) Cwmpas y caffaeliad
II.1.1) Teitl
NHS Genomic Medicine Service - Most Suitable Provider Process
Cyfeirnod: C368833
II.1.2) Prif god CPV
85100000
II.1.3) Y math o gontract
Gwasanaethau
II.1.4) Disgrifiad byr
This is a notice of intention to make an award in respect of the NHS Genomic Medicine Service pursuant to the Most Suitable Provider (MSP) Process for the NHS Genomic Medicine Service (NHS GMS). For the avoidance of doubt, this is an intention to award notice. A notice of the confirmation of the award of each contract will be issued once they are signed.<br/><br/>Pursuant to the NHS GMS contracts, provider are to provide the following functions: <br/>• Organisational leadership, governance and partnership arrangements;<br/>• Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>• Laboratory operating model;<br/>• Clinical function: cancer genomics;<br/>• Clinical function: rare disease;<br/>• Clinical function: population health;<br/>• Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>• Transformation and Service Improvement;<br/>• People – workforce, education and training; and<br/>• Data and digital
II.1.6) Gwybodaeth am lotiau
Mae’r contract hwn wedi’i rannu’n lotiau:
Ydy
II.1.7) Cyfanswm gwerth y caffaeliad
Gwerth heb gynnwys TAW: 5 175 000 000.00 GBP
II.2) Disgrifiad
Rhif y Lot 1
II.2.1) Teitl
Lot 1 – NHS North-West GMS
II.2.2) Cod(au) CPV ychwanegol
85100000
II.2.3) Man cyflawni
Cod NUTS:
UKD
II.2.4) Disgrifiad o’r caffaeliad
Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People – workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is £5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
II.2.5) Meini prawf dyfarnu
Maen prawf cost: Most suitable provider process with regard to the key Criteria
/ Pwysoliad: 100
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Ydy
Disgrifiad o’r opsiynau:
Options to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period.
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 2
II.2.1) Teitl
Lot 2 – NHS North-East and Yorkshire GMS
II.2.2) Cod(au) CPV ychwanegol
85100000
II.2.3) Man cyflawni
Cod NUTS:
UKC
II.2.4) Disgrifiad o’r caffaeliad
Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People – workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is £5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
II.2.5) Meini prawf dyfarnu
Maen prawf cost: Most suitable provider process with regard to the key Criteria
/ Pwysoliad: 100
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Ydy
Disgrifiad o’r opsiynau:
Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 3
II.2.1) Teitl
Lot 3 – NHS Central and South GMS
II.2.2) Cod(au) CPV ychwanegol
85100000
II.2.3) Man cyflawni
Cod NUTS:
UKG
II.2.4) Disgrifiad o’r caffaeliad
Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People – workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is £5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
II.2.5) Meini prawf dyfarnu
Maen prawf cost: Most suitable provider process with regard to the key Criteria
/ Pwysoliad: 100
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Ydy
Disgrifiad o’r opsiynau:
Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 4
II.2.1) Teitl
Lot 4 – NHS East GMS
II.2.2) Cod(au) CPV ychwanegol
85100000
II.2.3) Man cyflawni
Cod NUTS:
UKH
II.2.4) Disgrifiad o’r caffaeliad
Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People – workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is £5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
II.2.5) Meini prawf dyfarnu
Maen prawf cost: Most suitable provider process with regard to the key Criteria
/ Pwysoliad: 100
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Ydy
Disgrifiad o’r opsiynau:
Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 5
II.2.1) Teitl
Lot 5 – NHS South-West GMS
II.2.2) Cod(au) CPV ychwanegol
85100000
II.2.3) Man cyflawni
Cod NUTS:
UKK
II.2.4) Disgrifiad o’r caffaeliad
Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People – workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is £5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
II.2.5) Meini prawf dyfarnu
Maen prawf cost: Most suitable provider process with regard to the key Criteria
/ Pwysoliad: 100
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Ydy
Disgrifiad o’r opsiynau:
Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 6
II.2.1) Teitl
Lot 6 – NHS North Thames GMS
II.2.2) Cod(au) CPV ychwanegol
85100000
II.2.3) Man cyflawni
Cod NUTS:
UKI
II.2.4) Disgrifiad o’r caffaeliad
Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People – workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is £5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
II.2.5) Meini prawf dyfarnu
Maen prawf cost: Most suitable provider process with regard to the key Criteria
/ Pwysoliad: 100
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Ydy
Disgrifiad o’r opsiynau:
Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 7
II.2.1) Teitl
Lot 7 – NHS South-East GMS
II.2.2) Cod(au) CPV ychwanegol
85100000
II.2.3) Man cyflawni
Cod NUTS:
UKJ
II.2.4) Disgrifiad o’r caffaeliad
Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People – workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is £5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
II.2.5) Meini prawf dyfarnu
Maen prawf cost: Most suitable provider process with regard to the key Criteria
/ Pwysoliad: 100
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Ydy
Disgrifiad o’r opsiynau:
Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Section IV: Gweithdrefn
IV.1) Disgrifiad
IV.1.1) Y math o weithdrefn
Dyfarnu contract heb gyhoeddi galwad am gystadleuaeth yng Nghyfnodolyn Swyddogol yr Undeb Ewropeaidd ymlaen llaw
Cyfiawnhau'r weithdrefn ddyfarnu a ddewiswyd:
Mae’r caffaeliad y tu allan i gwmpas cymhwysiad y gyfarwyddeb
Esboniad
This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act Regulations 2023 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to decision makers by Tuesday 4th November 2025. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.
IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)
The procurement is covered by the Government Procurement Agreement:
Na
IV.2) Gwybodaeth weinyddol
IV.2.1) Cyhoeddiad blaenorol mewn perthynas â’r weithdrefn hon
Rhif yr hysbysiad yn OJ S:
2025/S 000-042969
Section V: Dyfarnu contract
Rhif y Lot: 1
Teitl: Lot 1 - NHS North-West GMS
Dyfernir contract/lot:
Ydy
V.2 Dyfarnu contract
V.2.1) Y dyddiad y daeth y contract i ben
21/10/2025
V.2.2) Gwybodaeth am dendrau
Nifer y tendrau a ddaeth i law: 3
Dyfarnwyd y contract i gr?p o weithredwyr economaidd:
Na
V.2.3) Enw a chyfeiriad y contractwr
Manchester University NHS Foundation Trust
Manchester
UK
NUTS: UKD3
BBaCh yw’r contractwr:
Na
V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)
Cyfanswm gwerth y contract/lot: 5 175 000 000.00 GBP
V.2.5) Gwybodaeth am is-gontractio
Section V: Dyfarnu contract
Rhif y Lot: 2
Teitl: Lot 2 - NHS North-East and Yorkshire GMS
Dyfernir contract/lot:
Ydy
V.2 Dyfarnu contract
V.2.1) Y dyddiad y daeth y contract i ben
21/10/2025
V.2.2) Gwybodaeth am dendrau
Nifer y tendrau a ddaeth i law: 3
Dyfarnwyd y contract i gr?p o weithredwyr economaidd:
Na
V.2.3) Enw a chyfeiriad y contractwr
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle
UK
NUTS: UKC2
BBaCh yw’r contractwr:
Na
V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)
Cyfanswm gwerth y contract/lot: 5 175 000 000.00 GBP
V.2.5) Gwybodaeth am is-gontractio
Section V: Dyfarnu contract
Rhif y Lot: 3
Teitl: Lot 3 NHS Central and South GMS
Dyfernir contract/lot:
Ydy
V.2 Dyfarnu contract
V.2.1) Y dyddiad y daeth y contract i ben
21/10/2025
V.2.2) Gwybodaeth am dendrau
Nifer y tendrau a ddaeth i law: 3
Dyfarnwyd y contract i gr?p o weithredwyr economaidd:
Na
V.2.3) Enw a chyfeiriad y contractwr
Birmingham Women’s and Children’s NHS Foundation Trust
Birmingham
UK
NUTS: UKG3
BBaCh yw’r contractwr:
Na
V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)
Cyfanswm gwerth y contract/lot: 5 175 000 000.00 GBP
V.2.5) Gwybodaeth am is-gontractio
Section V: Dyfarnu contract
Rhif y Lot: 4
Teitl: Lot 4 NHS East GMS
Dyfernir contract/lot:
Ydy
V.2 Dyfarnu contract
V.2.1) Y dyddiad y daeth y contract i ben
21/10/2025
V.2.2) Gwybodaeth am dendrau
Nifer y tendrau a ddaeth i law: 3
Dyfarnwyd y contract i gr?p o weithredwyr economaidd:
Na
V.2.3) Enw a chyfeiriad y contractwr
Cambridge University Hospitals NHS Foundation Trust
Cambridge
UK
NUTS: UKH1
BBaCh yw’r contractwr:
Na
V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)
Cyfanswm gwerth y contract/lot: 5 175 000 000.00 GBP
V.2.5) Gwybodaeth am is-gontractio
Section V: Dyfarnu contract
Rhif y Lot: 5
Teitl: Lot 5 NHS South-West GMS
Dyfernir contract/lot:
Ydy
V.2 Dyfarnu contract
V.2.1) Y dyddiad y daeth y contract i ben
21/10/2025
V.2.2) Gwybodaeth am dendrau
Nifer y tendrau a ddaeth i law: 3
Dyfarnwyd y contract i gr?p o weithredwyr economaidd:
Na
V.2.3) Enw a chyfeiriad y contractwr
North Bristol NHS Trust
Bristol
UK
NUTS: UKK1
BBaCh yw’r contractwr:
Na
V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)
Cyfanswm gwerth y contract/lot: 5 175 000 000.00 GBP
V.2.5) Gwybodaeth am is-gontractio
Section V: Dyfarnu contract
Rhif y Lot: 6
Teitl: Lot 6 NHS North Thames GMS
Dyfernir contract/lot:
Ydy
V.2 Dyfarnu contract
V.2.1) Y dyddiad y daeth y contract i ben
21/10/2025
V.2.2) Gwybodaeth am dendrau
Nifer y tendrau a ddaeth i law: 3
Dyfarnwyd y contract i gr?p o weithredwyr economaidd:
Na
V.2.3) Enw a chyfeiriad y contractwr
Great Ormond Street Hospital for Children NHS Foundation Trust
London
UK
NUTS: UKI3
BBaCh yw’r contractwr:
Na
V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)
Cyfanswm gwerth y contract/lot: 5 175 000 000.00 GBP
V.2.5) Gwybodaeth am is-gontractio
Section V: Dyfarnu contract
Rhif y Lot: 7
Teitl: Lot 7 NHS South-East GMS
Dyfernir contract/lot:
Ydy
V.2 Dyfarnu contract
V.2.1) Y dyddiad y daeth y contract i ben
21/10/2025
V.2.2) Gwybodaeth am dendrau
Nifer y tendrau a ddaeth i law: 3
Dyfarnwyd y contract i gr?p o weithredwyr economaidd:
Na
V.2.3) Enw a chyfeiriad y contractwr
Guy's and St Thomas' NHS Foundation Trust
London
UK
NUTS: UKI3
BBaCh yw’r contractwr:
Na
V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)
Cyfanswm gwerth y contract/lot: 5 175 000 000.00 GBP
V.2.5) Gwybodaeth am is-gontractio
Section VI: Gwybodaeth ategol
VI.3) Gwybodaeth ychwanegol
This is a Provider Selection Regime (PSR) intention to award notice. This intention to award notice is subject to Regulation 10(7) of the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act Regulations 2023 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to the relevant authority by midnight on Tuesday 4th November 2025. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.<br/>Written representations should be sent to england.genomics@nhs.net, ensuring the following details are referenced:<br/>Project reference: C368833<br/>Project title: NHS Genomic Medicine Service - Most Suitable Provider process<br/>This decision has been made as per NHS England governance processes, by the Commercial Executive Group on 14th October 2025 and the National Commissioning Group on 21st October 2025. No conflicts of Interest were identified amongst decision-makers.<br/>Each of the 5 key criteria were balanced with equal priority and considered on this basis and consideration was given to the basic selection criteria. Following provider assessments, it was agreed that the providers are the only providers capable of meeting the service specifications and requirements of the NHS GMS in full.<br/><br/>Additional CPV codes include:<br/>85145000-7 (Services provided by medical laboratories),<br/>85148000-8 (Medical analysis services)<br/>85111810-1 (Blood analysis services)<br/>85121200-5 (Medical specialist services)<br/>85140000-2 (Miscellaneous health services)
VI.4) Gweithdrefnau adolygu
VI.4.1) Corff adolygu
NHS Arden and Greater East Midlands Commissioning Support Unit
Cardinal Square, 10 Nottingham Road
Derby
DE1 3QT
UK
Cyfeiriad(au) rhyngrwyd
URL: https://www.ardengemcsu.nhs.uk/
VI.5) Dyddiad anfon yr hysbysiad hwn
23/10/2025